Clik here to view.
Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line...
KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received new approvals from the Japan Pharmaceuticals...
View ArticleClik here to view.
China National Medical Products Administration Approves Vosevi® (Sofosbuvir,...
FOSTER CITY, Calif. Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Medical Products Administration (NMPA) has approved Vosevi® (sofosbuvir 400mg/velpatasvir...
View ArticleClik here to view.
OncoSec Responds to Alpha’s “Proposal”
SAN DIEGO & PENNINGTON, N.J. OncoSec Medical Incorporated (NASDAQ:ONCS), (the “Company” or “OncoSec”) today issued the following response to the latest press release from Alpha Holdings, Inc....
View ArticleClik here to view.
ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved...
View ArticleClik here to view.
Invicro LLC Announces Dr. Matthew Silva as New Chief Executive Officer and...
BOSTON Invicro LLC, a Konica Minolta company, today announces, Dr. Matthew Silva has been appointed as the new Chief Executive Officer. Dr. Silva will assume the day-to-day leadership...
View ArticleClik here to view.
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the...
FOSTER CITY, Calif. & TOKYO Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) announced today that Gilead Sciences K.K. (Tokyo, Japan) and Eisai have entered into an...
View ArticleClik here to view.
インヴィクロがマシュー・シルビア博士の新最高経営責任者への任命とジャック・ホッピン博士のコニカミノルタプレシジョンメディシン社長への任命を発表
ボストン （ビジネスワイヤ） —...
View ArticleClik here to view.
Invicro LLC宣布Matthew Silva博士为新任首席执行官，Jack Hoppin博士被任命为Konica Minolta...
波士顿 (美国商业资讯)–柯尼卡美能达(Konica Minolta)旗下公司Invicro LLC今天宣布，Matthew Silva博士已被任命为公司新任首席执行官。Silva博士将负责公司的日常领导工作，并将加入Invicro董事会，即刻生效。Invicro联合创始人Jack Hoppin博士将不再担任Invicro首席执行官，转而出任Konica Minolta Precision...
View ArticleClik here to view.
Shinkowa Pharmaceutical: Notice for the Conclusion of NMN Product’s Material...
TOKYO Shinkowa Pharmaceutical Co., Ltd. (Head Office: Chuo Ward, Tokyo CEO: Megumi Tanaka) sells Nutraceuticals and cosmetics containing more than 99% high purity β-nicotinamide mononucleotide...
View ArticleClik here to view.
Sinovac Announces Approval of Varicella Vaccine for Prevention of...
BEIJING Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products...
View ArticleClik here to view.
Starpharma: Commencement of Phase 1 Trial for AZD0466 Utilising DEP® Delivery...
MELBOURNE, Australia Starpharma (ASX:SPL, OTCQX:SPHRY) today announced that AstraZeneca (LSE/STO/NYSE:AZN) has commenced a phase 1 clinical trial of AZD0466 (DEP® Bcl2/xL conjugate) and the first...
View ArticleClik here to view.
三叶草生物制药在中国开展的依那西普生物类似药SCB-808 III期临床试验入组首例患者
北京 (美国商业资讯)–三叶草生物制药，一家全球临床阶段，致力于创新及变革性生物制药研发的生物制药公司，今天宣布在中国开展SCB-808 III期临床试验入组首例患者。该药物是一种预充填小容量注射液Enbrel®（依那西普）的生物类似药，用于治疗风湿性疾病的适应症包括强直性脊柱炎和类风湿关节炎。...
View ArticleClik here to view.
Clover Biopharmaceuticals Initiates Phase III Study of Etanercept Biosimilar...
BEIJING Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed...
View ArticleClik here to view.
Urovant Sciences Majority Shareholder, Roivant Sciences, and Sumitomo...
IRVINE, Calif. & BASEL, Switzerland Urovant Sciences (Nasdaq: UROV) (“Urovant”) announced today that its majority shareholder, Roivant Sciences Ltd. (“Roivant”), and Sumitomo Dainippon Pharma...
View ArticleClik here to view.
Urovant Sciences Enters into $300 Million Term Loan Agreement with Sumitomo...
IRVINE, Calif. & BASEL, Switzerland Urovant Sciences (Nasdaq: UROV) (“Urovant”) announced today that it has entered into a $300 million term loan facility with Sumitomo Dainippon Pharma Co.,...
View ArticleClik here to view.
Urovant Sciences Announces Submission of New Drug Application for Vibegron...
IRVINE, Calif. & BASEL, Switzerland Urovant Sciences (Nasdaq: UROV) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking...
View ArticleClik here to view.
Psomagen-Macrogen Consortium Acquires All Patents and Data From US Company...
ROCKVILLE, Md. On January 2nd, the Psomagen-Macrogen Consortium announced the acquisition of all key assets of US company uBiome. Through the move, Psomagen has become a key player in the microbiome...
View ArticleClik here to view.
PMC Group完成对朗盛旗下有机锡特种产品业务资产的收购
新泽西州芒特劳雷尔 (美国商业资讯)–PMC Group N.A., Inc.（简称“PMC”）和Lanxess Organometallics GmbH（简称“朗盛”）已宣布， PMC已完成对朗盛旗下有机锡特种产品线（简称“业务”）的收购。该交易此前于2019年11月13日宣布，已于2019年12月30日正式完成。该业务包括朗盛旗下全球有机锡催化剂、有机锡特种品和中间体产品线。 关于PMC...
View ArticleClik here to view.
Clik here to view.
ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate,...
View Article